A perspective on the widening gap between Covishield vaccine doses in India

Authors

DOI:

https://doi.org/10.47203/IJCH.2021.v33i03.026

Keywords:

Covishield, Serum Institute of India, Vaccine Shortage

Abstract

The Oxford University-AstraZeneca’s vector-based vaccine called Covishield (ChAdOx1 nCoV- 19 Vaccine) is being manufactured and distributed by Serum Institute of India (SII).  National roll out of this vaccine was in a phased manner starting from 16th January 2021. At present, many states are facing shortage of vaccines. Government of India kept changing its policy on dosing gap of Covishield vaccine based on researches. The latest recommendation citing “real-life evidence” from the UK is to extend the two doses of Covishield to 12-16 weeks. This reasonable approach will not only a breathing space for the government but also aids in free up doses for a larger number of people to get their first dose of the vaccine.

Downloads

Download data is not yet available.

Published

2021-09-30

How to Cite

1.
Chellamuthu L, Sarathamani SS, Boratne AV. A perspective on the widening gap between Covishield vaccine doses in India. Indian J Community Health [Internet]. 2021 Sep. 30 [cited 2021 Dec. 5];33(3):541-2. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/2159

Issue

Section

Perspective